Alpine Immune Sciences (NASDAQ:ALPN) Stock Rating Reaffirmed by TD Cowen

Alpine Immune Sciences (NASDAQ:ALPN)‘s stock had its “hold” rating reissued by equities research analysts at TD Cowen in a research note issued to investors on Tuesday, Benzinga reports.

ALPN has been the subject of several other research reports. Royal Bank of Canada reiterated a “sector perform” rating and issued a $65.00 price objective (up previously from $41.00) on shares of Alpine Immune Sciences in a research note on Thursday, April 11th. SVB Leerink cut shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $42.00 to $65.00 in a research report on Friday, April 12th. Wedbush cut shares of Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research report on Thursday, April 11th. Guggenheim initiated coverage on shares of Alpine Immune Sciences in a research report on Tuesday, April 9th. They issued a “buy” rating and a $55.00 target price for the company. Finally, Wolfe Research restated a “peer perform” rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Eight analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $50.33.

Alpine Immune Sciences Stock Down 0.1 %

Shares of Alpine Immune Sciences stock opened at $64.46 on Tuesday. Alpine Immune Sciences has a twelve month low of $6.71 and a twelve month high of $64.57. The company has a 50-day simple moving average of $38.66 and a two-hundred day simple moving average of $24.15. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of -100.72 and a beta of 1.14.

Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings data on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.47. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. The business had revenue of $30.85 million during the quarter, compared to analysts’ expectations of $6.90 million. On average, sell-side analysts anticipate that Alpine Immune Sciences will post -1.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpine Immune Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Alpine Immune Sciences by 745.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,312 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Alpine Immune Sciences by 99.1% during the 2nd quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,315 shares during the last quarter. ADAR1 Capital Management LLC bought a new stake in Alpine Immune Sciences during the 4th quarter worth approximately $58,000. AJOVista LLC bought a new stake in Alpine Immune Sciences during the 4th quarter worth approximately $64,000. Finally, Public Employees Retirement System of Ohio bought a new stake in Alpine Immune Sciences during the 3rd quarter worth approximately $35,000. 75.17% of the stock is owned by institutional investors.

About Alpine Immune Sciences

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.